Biophan-die neue Microsoft?!
Seite 53 von 113 Neuester Beitrag: 26.07.23 00:01 | ||||
| Eröffnet am: | 15.05.04 09:58 | von: aida73 | Anzahl Beiträge: | 3.824 |
| Neuester Beitrag: | 26.07.23 00:01 | von: MrTrillion3 | Leser gesamt: | 361.019 |
| Forum: | Hot-Stocks | Leser heute: | 99 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 50 | 51 | 52 | | 54 | 55 | 56 | ... 113 > | ||||
Kurse werden leider in USA gemacht, aber ich glaube sie wird bald ausbrechen.
Schönes Wochenende an alle die investiert sind
megalith
wir sollten gerade jetzt sehr gespannt und aufmerksam die Biophan beobachten.Es geht jetzt sehr schnell.
Weiner schiebe eine Meldung hinterher.Wenn du diese gibst,wird der Kurs abgehen und die MM´s werden das nachsehen haben.Das bekommen die dann nicht mehr gehalten.Es ist echt unglaublich,wie die den Kurs mit aller Kraft festhalten.
Heute ist der 28.02.Weiner hat dieses Datum für eine Mega news angekündigt.Entweder kommt sie heute noch und es gibt einen unaufhaltsammen RUn oder wir halten und gehen ein wenig runter.
Wir sind der Meinung,es brodelt kräftigst.Hier ist mächtig was im Anmarsch.Harren wir der Dinge und sehen was am Nachmittag in USA läuft.
Liest mn sämtliche Analystensides im Netz,wird immer wieder Biophan erwähnt.
Also liebe Shareholder´s,wir sollten sehr aufmerksam schauen und uns überraschen lassen.
Wednesday March 2, 6:00 am ET
Company Chief to Discuss Market Growth Potential in Nanotechnology and Other Solutions in Multi-Billion Dollar Healthcare Sectors
ROCHESTER, N.Y.--(BUSINESS WIRE)--March 2, 2005-- Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation biomedical technology, has announced that Chief Executive Officer, Michael Weiner, will be presenting today at the Wall Street Analyst Forum, an annual conference that brings together analysts and other investment professionals in the financial community. The 16th annual forum runs February 28-March 2, at the Roosevelt Hotel in New York City.
ADVERTISEMENT
Mr. Weiner will speak on Biophan's progress in improving medical equipment and devices, including making devices function effectively with MRI, and increasing the life span of implantable devices with a new battery with extended life, powered by body heat. His address is scheduled to begin at 11:40 am Eastern. To access the live webcast, visit www.analyst-conference.com and click on the link near the top of the page, labeled, "February 28th-March 2nd, 2005 Webcast." When the schedule of conference events appears, select "Wednesday, March 2," and then select, "Biophan Technologies." The simple webcast registration process will then initiate.
"The Wall Street Analyst Forum and the webcast provide an excellent platform for Biophan and other participating companies to reach interested investors and communicate the latest developments in our fields, as well as to describe important market conditions and opportunities," said Mr. Weiner.
Biophan and its licensors currently hold 108 patents, licenses or patent applications in a range of solutions, many of them involving advances in nanotechnology. The Company possesses a range of proprietary solutions that enable many medical devices and equipment, such as pacemakers and stents, to be used safely and/or effectively with Magnetic Resonance Imaging (MRI) devices. Many medical devices have been difficult to image, or unsafe with MRI, one of the most important imaging tools in medicine. Additional technology can extend the life of implanted devices by converting body heat into electrical power.
About The Wall Street Analyst Forum
The Wall Street Analyst Forum has been sponsoring analyst conferences in New York, Boston and London since 1989. They have involved 2,500 different presenting NYSE/NASDAQ/AMEX corporations and have been attended by more than 15,000 analysts and portfolio managers. Conferences have received coverage in major financial news outlets, including the Wall Street Journal, Barron's, CNBC, Bloomberg and others.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
NEWS for BSX PRINT THIS PAGE BIG FONT SMALL FONT
BSX 32.38 -0.32
Today 5 Dy 1 Mo 3 Mo 1 Yr 5 Yr
Biophan CEO Michael Weiner to Present Today at Wall Street Analyst Forum in New York City, Talk to Be Webcast Live
ROCHESTER, N.Y.
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
OR
Press Interviews:
Jennifer Gould, 212-843-8037
Company Chief to Discuss Market Growth Potential in Nanotechnology and Other Solutions in Multi-Billion Dollar Healthcare Sectors
Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced that Chief Executive Officer, Michael Weiner, will be presenting today at the Wall Street Analyst Forum, an annual conference that brings together analysts and other investment professionals in the financial community. The 16th annual forum runs February 28-March 2, at the Roosevelt Hotel in New York City.
Mr. Weiner will speak on Biophan's progress in improving medical equipment and devices, including making devices function effectively with MRI, and increasing the life span of implantable devices with a new battery with extended life, powered by body heat. His address is scheduled to begin at 11:40 am Eastern. To access the live webcast, visit www.analyst-conference.com and click on the link near the top of the page, labeled, " February 28th-March 2nd, 2005 Webcast." When the schedule of conference events appears, select " Wednesday, March 2," and then select, " Biophan Technologies." The simple webcast registration process will then initiate.
" The Wall Street Analyst Forum and the webcast provide an excellent platform for Biophan and other participating companies to reach interested investors and communicate the latest developments in our fields, as well as to describe important market conditions and opportunities," said Mr. Weiner.
Biophan and its licensors currently hold 108 patents, licenses or patent applications in a range of solutions, many of them involving advances in nanotechnology. The Company possesses a range of proprietary solutions that enable many medical devices and equipment, such as pacemakers and stents, to be used safely and/or effectively with Magnetic Resonance Imaging (MRI) devices. Many medical devices have been difficult to image, or unsafe with MRI, one of the most important imaging tools in medicine. Additional technology can extend the life of implanted devices by converting body heat into electrical power.
About The Wall Street Analyst Forum
The Wall Street Analyst Forum has been sponsoring analyst conferences in New York, Boston and London since 1989. They have involved 2,500 different presenting NYSE/NASDAQ/AMEX corporations and have been attended by more than 15,000 analysts and portfolio managers. Conferences have received coverage in major financial news outlets, including the Wall Street Journal, Barron's, CNBC, Bloomberg and others.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Copyright © 2005 Business Wire. All reproduction, other than for an individual user's reference, is prohibited without prior written permission.
News Copyright © 2005 Interest!ALERT All rights reserved.
| Quotes & Info |
|
| Biophan Technologies Inc (BIPH.OB) | At 10:42AM ET: 1.46  0.06 (4.29%) |
| MORE ON BIPH.OB |
QuotesSummaryReal-Time ECNOptionsHistorical PricesCharts Basic ChartTechnical AnalysisNews & InfoHeadlinesCompany EventsMessage BoardCompanyProfileKey StatisticsSEC FilingsCompetitorsIndustryAnalyst CoverageAnalyst OpinionAnalyst EstimatesResearch ReportsStar AnalystsOwnershipMajor HoldersInsider TransactionsInsider RosterFinancialsIncome StatementBalance SheetCash Flow |
|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Vorstandsvorsitzender von Biophan verfasst Artikel im Magazin Nanotech Briefs, erläutert Konvergenz von Nanotechnologie und Biotechnologie
( BW)(NY-BIOPHAN-TECHNOLOGIES)(BIPH) Vorstandsvorsitzender von Biophan verfasst Artikel im Magazin Nanotech Briefs, erläutert Konvergenz von Nanotechnologie und Biotechnologie
Redaktion Wirtschaft/Biotech
ROCHESTER, N.Y.--(BUSINESS WIRE) - 3. März 2005-- Zu den Hauptthemen des Artikels gehören Durchbrüche in der Medizin durch Nanotechnologie
Biophan Technologies, Inc. (OTCBB:BIPH), ein Innovationsunternehmen, das biomedizinische Technologie der nächsten Generation entwickelt, meldete die Veröffentlichung eines vom Vorstandsvorsitzenden des Unternehmens, Michael Weiner, verfassten Artikels in der Januar 2005-Ausgabe von Nanotech Briefs. Nanotech Briefs ist ein Branchenfachblatt, das sich mit der Nanotechnologie und ihren Anwendungen beschäftigt. Der Artikel erscheint in der Spalte "Perspective" und trägt den Titel "The convergence of Biotechnology and Nanotechnology".
Weiner beleuchtet in dem Artikel die beschleunigte Erweiterung des Kenntnisstands in Medizin und Technik als Ergebnis der Konvergenz der beiden Fachbereiche Biotechnologie und Nanotechnologie in Kombination mit anderen Fortschritten, die während der vergangenen 30 Jahre erzielt worden sind.
"Die unglaublichen Fortschritte, die wir auf der Basis unseres sich gegenseitig ergänzenden und immer umfangreicher werdenden Wissensstands und der Innovationen in den beiden Bereichen erzielen, werden mit zunehmender Konvergenz von Nanotechnologie und Biotechnologie bald zu wirklich erstaunlichen Durchbrüchen führen", schreibt Weiner.
Weiner zitiert Experten wie Dr. med. Andrew C. Von Eschenbach, den Direktor des U.S. Department of Health & Human Services der National Institutes of Health, der es für möglich hält, dass Innovationen in der Nanotechnologie bis zum Jahr 2015 zur Entwicklung eines Heilmittels gegen Krebs geführt haben.
Weiner zählt auch Malaria, Herzerkrankungen und Diabetes zu der Liste an schweren Krankheiten, die mithilfe der Nanotechnologie bekämpft werden könnten. Darüber hinaus, so schreibt er, trägt die Nanotechnologie in signifikanter Weise zum Kampf gegen neue Gesundheitsgefahren bei, darunter gegen die Evolution neuer Viren oder von Biowaffen.
Interessenten steht der gesamte Artikel auf der Webseite von Biophan unter www.biophan.com/NB_Perspective_0105.pdf zur Verfügung.
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Ohne ne Unterstützung werden wir die Marke sicher net durchbrechen.
Vertauen scheint auch dazusein der Kurs bleibt ziemlich stabil.
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Vertauen scheint auch dazusein der Kurs bleibt ziemlich stabil.
Berlin sogar 1,18 und in den USA bleibts an der 1,50 kleben.
Gruß
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Boston Scientific to Announce Results from its TAXUS V Drug-Eluting Stent Clinical Trial, Studying Most Challenging Lesions and Highest-Risk Patients
Company to host meeting with financial analysts NATICK, Mass. - PRNewswire-FirstCall - March 3
NATICK, Mass., March 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs from March 6 to 9 in Orlando, Florida.
Sunday, March 6
TAXUS V Results. At 10:15 a.m., the Company will release nine-month results from its TAXUS V clinical trial, which is assessing the safety and efficacy of its TAXUS(R) Express2(TM) paclitaxel-eluting stent system. TAXUS V expands on the TAXUS IV pivotal trial by studying a higher-risk patient population, including patients with small vessels, large vessels and long lesions requiring multiple overlapping stents -- the most challenging lesions and highest-risk patients ever studied in a randomized controlled drug-eluting stent trial in the U.S. The results will be presented by Gregg W. Stone, M.D., the study's Principal Investigator, at a scientific session in Hall A of the Orange County Convention Center, 9800 International Drive, Orlando, at 10:15 a.m. The Company will also issue a press release at that time.
DES Educational Symposium. At 7:30 p.m., the Company will host a symposium entitled, " TAXUS Stent - The New Evidence: Expanding the Frontier" in Ballroom G of the Rosen Centre Hotel, 9840 International Drive, Orlando. The Company will host a reception prior to the symposium from 7:00 to 7:30 p.m. outside Ballroom G.
Monday, March 7
Analyst Meeting. At 7:30 a.m., the Company will host an analyst meeting in the Grand Ballroom of the Rosen Centre Hotel. The meeting is open to the media. This meeting is being webcast and can be accessed at Boston Scientific's website, http://www.bostonscientific.com/. Please visit the website beginning March 6 for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins. A replay of the webcast will be archived and available for 10 business days in the Webcast and Archives section of the Investor Relations site at http://www.bostonscientific.com/ beginning at approximately 1:00 p.m. ET on March 7 and running through Tuesday, March 22.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569 (Office)
617-834-8595 (Mobile)
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541 (Office)
508-667-5165 (Mobile)
Media Relations
Boston Scientific Corporation
Boston Scientific Corporation
Web site: http://www.bostonscientific.com/
|
|
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |
Da ist Gewaltig was im Busch anders kann ich es mir nicht erklären,die machen das doch nicht zum Geld wechseln.
Der Handel in Deutschland hat etwas spätdrauf reagiert,ich hab noch welche nachgeordert und heut morgen zu 1,21 bekommen "hätten günstiger sein können"
Gruß
Optionen
| Boardmail an "andy1964" |
Wertpapier: Biophan Technologies |